ClinicalTrials.gg
CompletedNCT03365102tDCSUpdated Feb 2, 2022Results posted

Modulating Impulsivity in Suicidal Adolescents With Transcranial Direct Current Stimulation (tDCS)

An interventional study of anodal tDCS over the rIFG, and anodal tDCS over the lOFC, in Impulsive Behavior, sponsored by Lifespan. Completed at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-02-02.

Sponsored by Lifespan · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2017, registered Aug 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Study summary

As a first step toward investigating whether modulation of impulsivity and associated neural pathways may yield clinically meaningful changes in risk for adolescent suicidal behavior, the R21 is a proof-of concept study evaluating the potential for tDCS targeting brain regions associated with behavioral impulsivity (right inferior frontal gyrus [rIFG]) and cognitive impulsivity (left orbitofrontal cortex [lOFC]) to modulate these facets of impulsivity in a sample of adolescent suicide attempters. Participants will be randomly assigned to receive anodal tDCS over the rIFG, anodal tDCS over the lOFC, or a sham stimulation condition, in a three-group design. Task-based measures of behavioral and cognitive impulsivity will be administered before and after tDCS or sham stimulation. Additionally, electroencephalography (EEG) and event-related potential (ERP) data will be collected during the impulsivity tasks, and resting-state EEG data will be collected pre- and post-tDCS administration to confirm engagement of the targeted brain regions and to delineating the neural pathways underlying the effects of tDCS on impulsivity.

Read the detailed description

Suicide is one of the leading causes of death in adolescence. To improve the ability to predict and prevent suicidal behavior, there is a pressing need for research in this area to advance beyond identifying risk factors toward a greater focus on the mechanisms of risk for this behavior. In particular, elucidating the neural pathways underlying risk for suicidal behavior is important insofar as such work may yield specific and modifiable targets for clinical intervention. The adoption of new experimental paradigms providing experimental control over potentially modifiable risk factors has been recommended as a means of meaningfully advancing the field in this regard. Although yet to be applied to the study of suicidality, transcranial direct current stimulation (tDCS), in conjunction with measures of electroencephalography (EEG) and event-related potentials (ERPs), may hold promise as an experimental paradigm in the study of potentially modifiable risk factors, and underlying neural mechanisms, for suicidality. One such risk factor of particular relevance to suicide in adolescence is state-sensitive aspects of impulsivity. Impulsivity has been consistently linked with suicidality, with this association appearing to be stronger in adolescence than adulthood. As a first step toward investigating whether modulation of impulsivity and associated neural pathways may yield clinically meaningful changes in risk for adolescent suicidal behavior, the R21 is a proof-of concept study evaluating the potential for tDCS targeting brain regions associated with behavioral impulsivity (right inferior frontal gyrus [rIFG]) and cognitive impulsivity (left orbitofrontal cortex [lOFC]) to modulate these facets of impulsivity in a sample of adolescent suicide attempters. Participants will be randomly assigned to receive anodal tDCS over the rIFG, anodal tDCS over the lOFC, or a sham stimulation condition, in a three-group design. Task-based measures of behavioral and cognitive impulsivity will be administered before and after tDCS or sham stimulation. Additionally, EEG and ERP data will be collected during the impulsivity tasks, and resting-state EEG data will be collected pre- and post-tDCS administration to confirm engagement of the targeted brain regions and to delineating the neural pathways underlying the effects of tDCS on impulsivity.

02

Conditions studied

  • Impulsive Behavior

Browse trials for

03

In context

Impulsive Behavior

158 studies on the registry are indexed under Impulsive Behavior; 31 are open to participants now.

This study's enrollment of 64 is above the median of 50 across 128 interventional studies indexed under Impulsive Behavior.

Browse Impulsive Behavior studies →

Lead sponsor

Lifespan is the lead sponsor of 26 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have attempted suicide prior to admission
  • speak and read English fluently
  • do not display evidence of significant cognitive impairment, based on a standard psychiatric exam as well as school records on admission
  • are not actively psychotic at time of intake.

Exclusion criteria

Exclusion Criteria:

  • a significant general medical condition
  • history of seizure, head injury, brain surgery or tumor
  • intracranial metallic implants or implanted electrical devices
  • substance abuse or dependence in the past six months.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    anodal tDCS over the rIFG,

    anodal tDCS over the rIFG,

    Device: anodal tDCS over the rIFG,

  • Experimental
    anodal tDCS over the lOFC

    anodal tDCS over the lOFC

    Device: anodal tDCS over the lOFC,

  • Placebo comparator
    sham tDCS stimulation

    sham tDCS stimulation

    Device: sham tDCS stimulation condition

Interventions

  • Deviceanodal tDCS over the rIFG,

    tDCS at a constant current of 1.5 milliampere (mA) will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.

  • Deviceanodal tDCS over the lOFC,

    tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.

  • Devicesham tDCS stimulation condition

    In the sham condition, the current will be ramped up to 1.5 mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.

06

What researchers measure

Primary outcomes

  1. Stop Signal Task (SST)

    The Stop-Signal Task (SST) is a task requiring inhibition of a prepotent motor response. The SST requires participants to respond to a target stimulus as quickly and accurately as possible by pressing a button, but also to withhold their response when they hear an auditory signal. Thus, this task involves a competition between activating and inhibiting processes. The primary outcome variable is change in the stop signal reaction time (SSRT) for the task administered seconds to minutes before and seconds to minutes after stimulation. The theoretical minimum is zero seconds and there is no theoretical maximum. Higher SSRT scores reflect greater impulsivity.

    Time frame: Within an hour post-stimulation condition

  2. Delay Discounting Task

    This task assessed discounting larger future rewards for smaller immediate ones. The point where a person is equally likely to prefer immediate vs delayed reward (the indifference point) is determined for several and combinations of reward sizes and lengths of time. Area under the curve (AUC) is calculated by summing the results of the following for each delay and indifference point pair: x2-x1\[(y1 + y2)/2\]. x1 and x2 are successive delays and y1 and y2 are indifference points for those delays. AUC range=0-1. Larger AUCs reflect less impulsivity.

    Time frame: Within an hour post-stimulation condition

07

Results

Posted Feb 2, 2022
Limitations and caveats
Multiple and persistent technical problems were experienced with the device used in this study. It was not possible to confirm that stimulation reliably occurred and that therefore all study participants received then intended stimulation. Caution should therefore be taken in interpreting the results of this study.

Participant flow

Participant flow — Overall Study
MilestoneAnodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS Stimulation
Started222220
Completed182119
Not completed411

Outcome measures

PrimaryStop Signal Task (SST)

The Stop-Signal Task (SST) is a task requiring inhibition of a prepotent motor response. The SST requires participants to respond to a target stimulus as quickly and accurately as possible by pressing a button, but also to withhold their response when they hear an auditory signal. Thus, this task involves a competition between activating and inhibiting processes. The primary outcome variable is change in the stop signal reaction time (SSRT) for the task administered seconds to minutes before and seconds to minutes after stimulation. The theoretical minimum is zero seconds and there is no theoretical maximum. Higher SSRT scores reflect greater impulsivity.

Time frame:
Within an hour post-stimulation condition
Reported as:
Mean · milliseconds
Stop Signal Task (SST)
millisecondsAnodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS Stimulation
Stop Signal Task (SST)255 ± 463215 ± 278297 ± 278
PrimaryDelay Discounting Task

This task assessed discounting larger future rewards for smaller immediate ones. The point where a person is equally likely to prefer immediate vs delayed reward (the indifference point) is determined for several and combinations of reward sizes and lengths of time. Area under the curve (AUC) is calculated by summing the results of the following for each delay and indifference point pair: x2-x1\[(y1 + y2)/2\]. x1 and x2 are successive delays and y1 and y2 are indifference points for those delays. AUC range=0-1. Larger AUCs reflect less impulsivity.

Time frame:
Within an hour post-stimulation condition
Reported as:
Mean · score on a scale
Delay Discounting Task
score on a scaleAnodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS Stimulation
Delay Discounting Task.53 ± .31.4 ± .25.57 ± .29

Adverse events

Collected over 1 hour. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anodal tDCS Over the rIFG,0/22 (0%)0/22 (0%)0/22 (0%)
Anodal tDCS Over the lOFC0/22 (0%)0/22 (0%)0/22 (0%)
Sham tDCS Stimulation0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

Data for participants who completed the study procedures are reported.

Age, Categorical
Age, Categorical(Participants)Anodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS StimulationTotal
<=18 years0000
Between 18 and 65 years18211958
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Anodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS StimulationTotal
Female14171445
Male44513
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Anodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS StimulationTotal
Hispanic or Latino55212
Not Hispanic or Latino13161746
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Anodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS StimulationTotal
American Indian or Alaska Native0011
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American3238
White7121231
More than one race76316
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(participants)Anodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS StimulationTotal
United States18211958
PROMIS Depression
PROMIS Depression(units on a scale)Anodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS StimulationTotal
Mean49 ± 1047 ± 1247 ± 1247.64285714 ± 11.22728587
Conners-3 Self-Report
Conners-3 Self-Report(units on a scale)Anodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS StimulationTotal
Inattention subscale16 ± 816 ± 915 ± 815.67857143 ± 8.250855918
Hyperactivity/impulsivity subscale14 ± 717 ± 712 ± 714.39285714 ± 7.191354839
Stop Signal Task
Stop Signal Task(milliseconds)Anodal tDCS Over the rIFG,Anodal tDCS Over the lOFCSham tDCS StimulationTotal
Mean353 ± 414276 ± 328233 ± 247284.8076923 ± 330.2148165

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Bradley Hospital
    Riverside, Rhode Island 02915, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Analysis files will be constructed from the stored electronic data and will be stripped of identifying information with the Safe Harbor method. Specifically, youth and their parents will be identified with a family identifier and person identifier number that is randomly generated and not related to any element of their personal identifying information. No names, addresses, telephone numbers, fax numbers, email addresses, social security numbers, medical records, etc. will be retained. Dates will contain only year and a randomly generated day-of-the-year. The investigators will only share it with external investigators when a data use agreement (DUA) is executed between Lifespan and the requester's institution. The DUA will specify the requested data elements (each of which must be justified), the specific research question, the timeline for the project, and schedule for data destruction. The data will be made available on April 1, 2021 by the PI

Supporting information: Study protocol, Informed consent form

Time frame: April 1, 2021

Access criteria: The investigators will only share it with external investigators when a data use agreement (DUA) is executed between the Brown University and the requester's institution. The DUA will specify the requested data elements (each of which must be justified), the specific research question, the timeline for the project, and schedule for data destruction.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Dec 2019, 32 months.

Results were first posted in Feb 2022, 2 years 1 month after primary completion. A results delay was requested in Feb 2021.

Of 55 non-industry interventional studies with no phase under Impulsive Behavior, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 34. This study's 32 months is above that.

Counting every sponsor, half of 55 studies reached it within 26 months; a quarter within 13 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2017
First posted
Dec 7, 2017
StartActual
Apr 1, 2017
Primary completionActual
Dec 31, 2019
CompletionActual
Dec 31, 2019
Results delay requested
Feb 17, 2021
Results first posted
Feb 2, 2022
Last update
Feb 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03365102
Lead sponsor
Lifespan
Responsible party
Richard Liu (Assistant Professor, Lifespan) — Principal investigator
First posted
Dec 7, 2017
Start date
Apr 1, 2017
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Results posted
Feb 2, 2022
Last update
Feb 2, 2022

Study contacts

Richard Liu, PhD
principal investigator · Lifespan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion